The Impact of GLP-1RA and SGLT2i on CKD Progression in Subjects with Diabetes | Peter Rossing, MD

In this ERA Symposium video, Dr. Peter Rossing, MD, discusses the evolving landscape of chronic kidney disease (CKD) management in individuals with diabetes, focusing on the impact of GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i). For many years, RAS blockade with ACE inhibitors or angiotensin II receptor blockers was the cornerstone of CKD treatment in diabetes. However, recent cardiovascular outcome trials have revealed that newer glucose-lowering agents, specifically SGLT2i and GLP-1RA, offer not only safe glucose reduction but also significant cardiovascular and kidney-protective benefits.

Dr. Rossing highlights key findings from these trials, showing that SGLT2 inhibitors can slow CKD progression and reduce cardiovascular events in patients with type 2 diabetes and CKD. Similarly, GLP-1 receptor agonists have shown potential kidney benefits, particularly in reducing albuminuria and preserving kidney function, though the studies were not primarily designed to evaluate these effects.

The discussion extends to the mechanisms behind these benefits and the potential for combining these agents with other treatments like RAS inhibitors and mineralocorticoid receptor antagonists (finerenone) for a more comprehensive approach to CKD management. With ongoing trials like FLOW offering promising data, this video provides crucial insights into the future of CKD care, including the possible applications in type 1 diabetes.

Join Dr. Rossing as he explores these groundbreaking advancements and their implications for the management of CKD in patients with diabetes.